Podcasts about prrt

Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms related to hormone excess, including carcinoid syndrome and carcinoid heart disease, managing symptoms of functioning pancreatic neuroendocrine tumors, and also palliative interventions. Dr. Perez and Del Rivero share how to use this guideline in concert with the systemic therapy for tumor control in metastatic well-differentiated GEP-NETs guideline, and hope for the future for the treatment of gastroenteropancreatic neuroendocrine tumors. Read the full guideline, “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Transcript This guideline, clinical tools, and resources are available on ASCO.org. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in JCO Oncology Practice.        Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Kim Perez from Dana-Farber Cancer Institute and Dr. Jaydira Del Rivero from the Center for Cancer Research at the National Cancer Institute, co-chairs on “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Thank you for being here today, Dr. Del Rivero and Dr. Perez. Dr. Kim Perez: Thank you. Dr. Jaydira Del Rivero: Thank you so much for the invitation. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Perez and Dr. Del Rivero, who have joined us here today, are available online with the publication of the guideline in JCO Oncology Practice, which is linked in the show notes. So then to jump into the content here, first Dr. Del Rivero, could you provide an overview of the scope and purpose of this guideline? Dr. Jaydira Del Rivero: Yeah. Thank you so much. Well, first, we really wanted to thank ASCO for allowing us to develop these guidelines for the management of gastroenteropancreatic neuroendocrine tumors. I do want to mention that there is also another set of guidelines that I was very fortunate also to co-chair with Dr. Perez on the systemic management of gastroenteropancreatic neuroendocrine tumors. But when discussing these guidelines as well as with the different panelists, experts in this type of disease, we also realized that the management of these tumors are quite complex, not only from the management of the disease progression, but at the same time, management of the symptoms related to the hormone excess. And because of that, we like to thank ASCO for allowing us to then not only have a discussion on the systemic management of these tumors, but at the same time develop recommendations for the symptoms related to the different hormones that these neuroendocrine tumors may produce. These guidelines are for the management of grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. These guidelines include the management of the different aspects and the symptoms related to hormone excess, such as carcinoid syndrome, carcinoid heart disease, how to manage carcinoid crisis, as well as the different symptoms and how to manage the functional pancreatic neuroendocrine tumors and as well as provide recommendations in the different treatments for these tumor types, not only from the systemic management but also from the surgical management as well as for liver-directed therapy options and the different aspects in terms of the palliative care of these patients to improve not only the symptoms related to the hormone excess caused by these tumors, but as well as to improve the quality of life. Brittany Harvey: Absolutely. And I appreciate that overview. And yes, we'll link the guideline on the Systemic Therapy for Tumor Control for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors in the show notes for our listeners so that they can refer to that companion guideline as well. So then you just described the several different categories of recommendations that this guideline covers on symptom management. So, Dr. Perez, I'd like to start reviewing some of those key recommendations of that guideline. So, starting with what are the key recommendations for carcinoid syndrome and carcinoid heart disease? Dr. Kim Perez: Thank you Brittany. Yeah, I also want to thank ASCO for inviting us to do this podcast today. Just to start, I think these guidelines will really add to what's available in the literature to provide a kind of a quick look for the community provider to manage carcinoid-related symptoms. I think the highlights that I would point out are we've all been using somatostatin analogs for the last few decades to manage symptoms, but with the newer treatments that are now available, we tried to highlight what does the literature support in regards to PRRT, what does the literature support in regards to using systemic therapy for disease management, but also the benefits that you will get from a symptom management perspective using other modalities. I think the highlight really is it's a multidisciplinary approach. We are now considering surgery and embolization or interventional radiology as a critical piece. And I think the third that I'd highlight is the fact that sometimes we get too focused on carcinoid syndrome and the symptoms will actually, may result from other things. And the highlight in the algorithms that we've provided is what other things cause carcinoid-related diarrhea. And let's not forget about that because we will find ourselves treating and patients getting very frustrated with persistence of symptoms when in actuality, we should be treating something else that is causing a very similar symptom. For carcinoid heart disease, I think there are more and more guidelines that are now available to provide guidance there, but I think the major advances are that we should be utilizing heart assessment with echocardiogram with lab values such as BMP. But also critical to this is consulting with our cardiology colleagues and making sure that we're identifying heart related issues that are resulting from hormone excess sooner than later because interventions on the earlier side can really make a significant impact on quality of life and associated comorbidities and mortality. Brittany Harvey: Thank you for reviewing those key points for both carcinoid syndrome and carcinoid heart disease symptom management. So then the next set of recommendations. Dr. Del Rivero, what are the key highlights for symptom management of functioning pancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: Yes, it's very important to recognize the symptoms related to hormone excess due to pancreas neuroendocrine tumors. Up to 10% of pancreas neuroendocrine tumors may produce different hormones. Among those hormones can be insulin, gastrin, glucagon, somatostatin. So it's important to know and understand that based on what a neuroendocrine tumor is, they may produce different types of hormones. The importance of these guidelines is to also recognize some of these symptoms and how to address that, because it's not necessarily in these tumor types besides the management of metastatic disease, and know the different options that we recommend for metastatic disease from the systemic therapy, such as chemotherapy or targeted therapies or PRRT. It's important to recognize the symptoms because based on the symptoms we may recommend a different approach. That's something that is important to acknowledge and recognize. Moreover, in certain functional pancreas neuroendocrine tumors, as Dr. Perez mentioned, is a multidisciplinary approach. And it's important to also discuss these different cases with your endocrinologist. You may need to have an experienced endocrinologist to manage, for example, the excess of insulin. And also discuss your cases with a surgeon and interventional radiologist because some of these approaches can certainly improve the symptoms related to hormone excess. I understand that sometimes medical oncologists in the communities may not have access to the multidisciplinary approach or have the different teams that can manage these tumors, and that's the reason why with these guidelines we wanted to establish the understanding of different symptoms associated with the hormone excess to these neuroendocrine tumors as well as how to manage this. For example, in the case of insulinoma, I think for the medical oncologist it is important to know that the everolimus is an option to be used for these tumors, not only to manage tumor progressions related to this tumor type at the same time, because everolimus as a side effect causes hyperglycemia, that can also improve some of the symptoms related to the excess of insulin besides the somatostatin agonist. I think these recommendations will allow the medical oncologist to recognize the symptoms and based on what the symptoms cause, then you can have a different approach that could be added to the systemic therapies options as well. Brittany Harvey: Yes, beyond systemic therapy, it's important to be recognizing symptoms to provide an individualized approach for every single patient. So then, following that overview of symptom management for functioning pancreatic neuroendocrine tumors, Dr. Perez, what is recommended regarding palliative interventions for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, great question. So I think what's unique to neuroendocrine tumors is that the palliative approach really mirrors what we would be doing for symptom management. Some of these patients are living a very long time with carcinoid related symptoms. And so the approach that we take for the carcinoid symptom control is going to mirror the palliative piece of it. I think for those who develop a burden of disease related symptoms, I think it mirrors what we do across the board for all cancer-related complications. And so I think what we attempted to highlight here and included one of our colleagues who focuses specifically on the field of palliative care and neuroendocrine tumors, was to never really lose sight of what we've been doing to care for symptom management throughout the patient's journey and to always rereview the etiology of the symptoms, ensure that we don't focus solely on carcinoid-related issues, but also the symptom management that we would apply to all patients with cancer-related burden symptoms. Brittany Harvey: Definitely. I think that's a helpful approach to consider when thinking about how to manage these palliative interventions as well. So then Dr. Del Rivero, what should clinicians know as they implement these symptom management recommendations? Dr. Jaydira Del Rivero: Yes, thank you so much for that question. As we have discussed in the last 10 or 15 minutes, we have discussed the different approaches on the management of gastroenteropancreatic neuroendocrine tumors. Clinicians, I think it's important to know that neuroendocrine tumors is a quite complex disease because we're not only addressing the management of tumor growth, but we're also addressing the management of the symptoms related to hormone excess and the complexity associated with that. When medical oncologists or clinicians implement these recommendations it's to understand what symptoms these tumors may cause related to the hormone excess but at the same time, how do we approach those symptoms? As Dr. Perez said that I think is very important is to recognize the different types of diarrhea. It doesn't mean that if the patient has worsening diarrhea, it doesn't mean that this is related to disease progression. So it's important to recognize so that way you can address that, because the type of diarrheas can be related because of the lanreotide or somatostatin agonist, it could be because of the prior surgery. I think it's important to recognize those in order to address the symptom. And the same with the gastroenteropancreatic neuroendocrine tumors. It's important to know what hormones they produce because there are different measurements that may be added to the systemic management of these tumors. I think that there are two aspects here, and that's the reason why these guidelines were implemented in the sense that not only we're going to manage disease progression of these tumors, or how do we manage the metastatic disease of these tumors, but at the same time, how do we manage the symptoms related to the hormone excess and the different complications. Moreover, I think, as we discussed earlier, we need to manage these tumors in a multidisciplinary approach. And something very important is not like one size fits all, because the treatment recommendations, it will depend on different characteristics in terms of the tumor presentations. And hormone excess is one of the important aspects to recognize so that way we can implement these recommendations that will definitely help the quality of life of these patients. Brittany Harvey: Absolutely. And using these guidelines in concert with the systemic therapy guidelines is key. And then beyond this impact for clinicians that Dr. Del Rivero has just outlined, Dr. Perez, what does this new guideline mean for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, I think that's an important highlight of this guideline. It really gives patients a voice. I think it recognizes the fact that these symptoms can go unmanaged or mismanaged or just missed, and patients commonly will come in feeling very frustrated and feeling very ill. And I think it will provide them a means to open up a conversation with their providers and say, “Hey, this is what I'm experiencing. Let's talk about what's available. How does this apply to me?” And I think that can be very empowering. I think it's really hard nowadays with so many sources and resources online and patients are really left wondering what are the bullet points that they should be bringing to their clinician appointments? And I think that these guidelines provide them a good framework for those discussions. Brittany Harvey: Yes, bringing these discussion points for patients is very important to be able to have those resources. And we have some patient resources and information available on the website for this guideline and we can link that in the show notes for listeners. So then you've both touched on the importance of this guideline for improving quality of life and we continue to see advancements in this field. So Dr. Del Rivera, what are the outstanding questions regarding symptom management and tumor control for gastroenteropancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: I have to say whenever somebody asks me that question, the word that I will say is I feel hopeful, because more than 10 years ago we didn't have that many options for gastroenteropancreatic neuroendocrine tumors. And it has been in the last decade or so that there has been more developments in the management of these tumors as well as the understanding of the symptoms related to these tumors. But that said, yes, we do need more therapies for gastroenteropancreatic neuroendocrine tumors. Of the treatment options that we have, we all know in the field that even though we have disease control by using the different options for the systemic management of gastroenteropancreatic neuroendocrine tumors, we need options where we can achieve an objective response, especially for these tumor types. But there is a significant volume of disease and we see a lot of these patients with gastroenteropancreatic neuroendocrine tumors. And now where the field is going is to make some of these therapies more effective, to develop more therapies as well. For example, immunotherapies, a different type of immunotherapy understand the tumor immune microenvironment of these tumors in order to develop therapies as well. From the antibody drug conjugates, I think that's a new way to also address or treat these tumor types, understanding about the different markers found on these tumors that way they can be addressed in different ways. Now with the development of new therapies, I think that's something that can help us as well not only have disease control and as well as having an objective response, but having a better objective response can certainly also help with the symptoms related to hormone excess too. In terms of other therapies, I think some of the issues that we encounter are like the refractory carcinoid diarrhea and how do we manage this. We do have therapies that can help us control the diarrhea in the refractory settings, such as telotristat. Telotristat is one of the newer medications that can help us control the refractory diarrhea. But that said, despite this, that we still encounter situations where it's sometimes difficult to control. I think in those situations it will be good to understand more about the biology of these tumors as well and how we manage. If there is a different time or how do we implement these options. I think there is so much to learn. But that said, I feel we're in hopeful times. We're understanding more about these tumors so that way we can help us develop better therapies not only to have control of the tumor growth as well having control of the symptoms. And it's the same with the pancreas neuroendocrine tumors in the metastatic setting. Sometimes it may be difficult to control this hormone excess. But understanding these and having therapies that can achieve more of an objective response, I think that will definitely help us more and manage these patients. But one aspect I want to mention, and Dr. Perez also mentioned as well, the fact that we have these guidelines that help us understand about the different symptoms related to hormone excess and how to address it, I think is very important because having symptoms related to hormone excess can be detrimental to the quality of life on patients with neuroendocrine tumors that may necessarily be related to disease progression and having this information is so important. And I'm hopeful for the different therapies. There's different clinical trials ongoing for neuroendocrine tumors and especially in the field of PRRT. And a lot of more information will come with the different alpha-PRRT and combination therapy. So more information to come in the next couple of years. So this is, in my opinion, hopeful times for this field. Brittany Harvey: It's great to hear that you're hopeful for all the developments in this field and we'll look forward to the development and discovery of new therapies and further research and then, hopefully incorporate those updates into guidelines in the future. So I want to thank you both so much for your work to develop these guidelines and thank you for your time today. Dr. Del Rivero and Dr. Perez. Dr. Jaydira Del Rivero: Thank you so much for having us. Dr. Kim Perez: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

When it comes to PRRT (Peptide Receptor Radionuclide Therapy), patients often have big questions and concerns. In this episode, we dive into the most common questions surrounding PRRT and the broader field of radiopharmaceutical treatments for neuroendocrine cancer. This is an exciting field as there is much more research being done into radiopharmaceuticals for neuroendocrine […] The post Radiopharmaceutical Treatment – FAQs & Insights appeared first on NETRF.

ABOUT THIS EPISODEWhat is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing.TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY FOR NEUROENDOCRINE CANCERS:1. What is radiation oncology? How does it work? How is it different from other types of radiation?2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective?Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used?Is there a number or size limit of the tumor(s)?4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it?If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT?If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated?How common is increased pain after treatment to the bone? What causes that?5. Safety: How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?)Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans?How often can these procedures be repeated? Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they?Is there a risk with fertility?What other risks are there?6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give?9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor?  How do you know if the treatment “worked”?Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment?For more information, visit LACNETS.org.

ABOUT THIS EPISODEIn this 2-part series, Dr. Osman Ahmed from the University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques, including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures.TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY PART 2:1. What do patients need to know about bland embolization (TAE)? a. What are the possible side effects? b. How do the size of beads play a role? c. When is this recommended? d. Do you always do both sides of the liver? If so, what is the timing and why? e. What is the recovery like? What is post-embolization syndrome?2. What do patients need to know about chemoembolization (TACE)?a. What drug is used & does this go through the whole body? b. What is the recovery like? What are the possible side effects?3. What do patients need to know about radioembolization (TARE, SIRT, y90)? a. In the era of PRRT, is there a concern with using y90 or radioembolization? How is the approach and technique used with radioembolization different than how it was done in the past? Is there a total lifetime limit of radiation?b. What is the recovery like? What are the possible side effects?4. Is there a limit to how much LDT one can do? Can they be repeated?5. How does one decide between the various types of liver-directed therapies?6. Is there a sequencing to treatments?7. Are there certain treatments that make you ineligible for other treatments? [PRRT, chemo, y90 etc] 8. If someone has had surgery such as a Whipple or surgery or procedures involving the bile duct, such as a stent in the bile duct or surgical removal of part of the bile duct, how does this weigh into the decision-making process for LDT?9. How do you determine if the treatment “worked?” What is the follow-up like? What scan might you do and in what timing?10. What do you see as the future of liver-directed therapy in neuroendocrine cancer treatment? MEET DR. OSMAN AHMEDOsman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology.Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology.For more information, visit https://www.lacnets.org/lacnets-podcastFor more information, visit LACNETS.org.

Únete a la Newsletter La Milla aquí: https://corre.lamilla.run/803e8890/  Maikel en instagram: https://www.instagram.com/lamilla.run/  ----- Código descuento PALABRADERUNNER en Styrpe. Código descuento PDR10 en nutrición fanté. Libro de Pfitzinger https://pdrun.es/libromaratonpfitz -  Libro de Daniels https://pdrun.es/libroformuladaniels -  ⚡Instagram: https://instagram.com/palabraderunner - Seguro de viaje Intermundial para cualquier país (descuento PALABRADERUNNER) https://pdrun.es/segurodeviaje - eSIM de datos Airalo (descuento PEDRO1993) https://pdrun.es/airaloesim - eSIM de datos ilimitada Holafly (descuento PALABRADERUNNER) https://pdrun.es/holafly

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including:The diagnosis and typical presenting symptoms of GEP-NETsFindings from recent key phase III studies including NETTER-2 and CABINETRecommendations for treatment sequencingNotable clinical pearls regarding GEP-NET therapiesCurrent guidelines for GEP-NET care and monitoringPresenters:Thor R. Halfdanarson, MDConsultant, Division of Medical OncologyProfessor of OncologyAssociate Professor of MedicineMayo Clinic Comprehensive Cancer CenterChair, Hepato-Pancreatico-Biliary Disease GroupRochester, MinnesotaJonathan StrosbergProfessor, GI OncologyChair, Neuroendocrine Tumor DivisionMoffitt Cancer Center and Research InstituteTampa, FloridaLink to full program: https://bit.ly/3Y0JWBa

What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy.TOP TEN QUESTIONS ABOUT CHEMOTHERAPY FOR NENS:What is chemotherapy? How does it work? What are the chemotherapy drugs used for neuroendocrine cancer? When are they used? Which neuroendocrine cancers are they used for? How does chemotherapy differ from other treatments such as SSAs or targeted therapies (everolimus, sunitinib, cabozantinib)? What side effects might someone have when taking chemotherapy? Will my hair fall out? How might it affect my day-to-day ability to work and function? Can I live a “normal life” while taking this medication? Do any of these side effects have long-lasting effects?Would taking chemotherapy cause someone to be immunocompromised?When in one's neuroendocrine journey might you recommend chemotherapy? Where does it fall in sequencing?How do you decide which chemotherapy medication to recommend? Can they be stopped and restarted? Can they be repeated? Can you take more than one drug in the category? Can they be taken in combination with another drug?Does taking chemotherapy preclude someone from getting another treatment in the future such as Lutathera PRRT or a clinical trial of alpha PRRT?What do you see as the future of chemotherapy in neuroendocrine cancer treatment? MEET PAMELA L. KUNZ, MDDr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA's Oncology Drug Advisory Committee. She was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021, she was awarded ‘Woman Oncologist of the Year' by Women Leaders in Oncology for her work in promoting gender equity.For more information, visit LACNETS.org.

This episode of NETs Get Real is brought to you by TerSera Theraputics and ITM Radio Pharma and we speak with Dr. Aman Chauhan from the University of Miami and he shares The Truth About PRRT! Please make sure to follow us on your preferred streaming platform and give us a 5 star rating! For more information please go to our website: http://www.netcancerawareness.org and follow us on social media @netcanceraware And visit our sponsors: TerSera Theraputics: https://tersera.com/ ITM Radiopharma: https://www.itm-radiopharma.com/home/

What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances.MEET DR. RIHAM EL KHOULI, MD, PHDAssociate Professor of Radiology, UK College of MedicineChief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R)Director, Radiotheranostics ProgramUniversity of KentuckyDr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine.TOP TEN QUESTIONS ABOUT NET TREATMENTS:1. What is PRRT?  How does it work? 2. What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT?3. How do you determine who is eligible for PRRT?4. When is PRRT given in one's treatment journey? 5. How does PRRT differ from other treatments?6. What are the common side effects of Lutathera?a. Does Lutathera have long-lasting effects?b. Would receiving Lutathera affect one's blood counts?c. How might Lutathera affect one's liver function? When, if ever is there concern about liver failure?7. How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? a. What precautions do I need to follow?b. Can I hug my child? Can I pet my dog? c. Would receiving Lutathera cause someone to be immunocompromised? 8. How to you decide who should get PRRT?a. What is peritoneal disease and how effective is PRRT with peritoneal disease?9. How do you assess the response to PRRT? 10. What advances in PRRT are you most excited about? Visit https://www.lacnets.org/podcast/34. For more information, visit LACNETS.org.

Charlamos con Estefanía Unzu, Campeona de España de 100km en ruta en su debut en ultradistancia y ha corrido 13 maratones en 13 meses. Hablamos de cómo ha sido este último año metida a fondo en el running. Puedes encontrar a Estefi en redes como https://www.instagram.com/verdeliss/ -  - Grandes descuentos en fitnessdigital por su 17 Aniversario (código PDR5FD para descuento extra): https://pdrun.es/fitnessdigital17 -  - Aquí recopilo las ofertas más destacadas del aniversario https://www.palabraderunner.com/ofertas-fitnessdigital-17-aniversario/ -  Código descuento PALABRADERUNNER en Styrpe. Código descuento PDR10 en nutrición fanté. Libro de Pfitzinger https://pdrun.es/libromaratonpfitz -  Libro de Daniels https://pdrun.es/libroformuladaniels -  ⚡Instagram: https://instagram.com/palabraderunner - Seguro de viaje Intermundial para cualquier país (descuento PALABRADERUNNER) https://pdrun.es/segurodeviaje - eSIM de datos Airalo (descuento PEDRO1993) https://pdrun.es/airaloesim - eSIM de datos ilimitada Holafly (descuento PALABRADERUNNER) https://pdrun.es/holafly

ABOUT THIS EPISODEWhat are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter's invisibility cloak in understanding treatment goals with NETs.MEET DR. SCOTT PAULSONDr. Paulson is a medical oncologist and the medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He also serves as the co-director of the Gastrointestinal Research Program for the Sarah Cannon Research Institute.Dr. Paulson earned his medical doctorate at The University of Texas Southwestern Medical School. He took his residency and an internship in internal medicine at Brigham and Women's Hospital in Boston, Massachuests. His fellowship was completed in medical oncology at the University of California, San Francisco.  Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. He currently is an investigator on a clinical trial studying nab-sirolimus, a mTOR inhibitor, which is a type of targeted therapy.TOP TEN QUESTIONS ABOUT TARGETED THERAPIES FOR NETs:1. What are targeted therapies?  Are they considered chemotherapy? How do they work?2. What are the different types of targeted therapies for NETs?3. When and how are targeted therapies used?4. What side effects might someone have when taking a targeted therapy? a.Can targeted therapies affect blood sugars or cause diabetes?b. Can targeted therapies cause one to be immunocompromised?c. Can targeted therapies affect one's blood counts?5. What is the goal of treatment with targeted therapies? (Why would one take these drugs given the potential side effects? Can the side effects be managed?)6. How do you decide which targeted therapy to recommend for a patient?7. Can a NET patient take more than one drug in this category? Can the medications be stopped and restarted?8. What is your approach with dosing?9. What is your approach with monitoring? What and how often do people need blood work?10. Does taking a targeted therapy preclude someone from getting another treatment in the future, such as Lutathera/PRRT, or a clinical trial of alpha PRRT?BONUS: What are the latest advances in targeted therapy? What is the future of targeted therapies?For more information, please visit https://www.lacnets.org/podcast/33. For more information, visit LACNETS.org.

Os cuento cómo fue mi carrera en la Zurich Rocknroll Running Series Madrid, sensaciones y estrategia en la segunda maratón en 7 días. Brazalete Coospo https://pdrun.es/coospohw9 -Vídeo completo de la carrera: https://youtu.be/i-UeWTsap0w -  Código descuento PALABRADERUNNER en Styrpe. Código descuento PDR10 en nutrición fanté. ⚡Instagram: https://instagram.com/palabraderunner - Seguro de viaje Intermundial para cualquier país (descuento PALABRADERUNNER) https://pdrun.es/segurodeviaje - eSIM de datos Airalo (descuento PEDRO1993) https://pdrun.es/airaloesim - eSIM de datos ilimitada Holafly (descuento PALABRADERUNNER) https://pdrun.es/holafly

Te cuento todo sobre las Nimbus Mirai, las zapatillas ASICS más sostenibles, y 100% reciclables. https://www.palabraderunner.com/asics-nimbus-mirai/ -

Respondo vuestras preguntas y dudas sobre la Maratón de Tokio, comparación con Berlín, nutrición en carrera, el porqué de la zapatilla, coste total del viaje, siguientes objetivos y mucho más. - Central Lechera Asturiana colabora con nosotros en este episodio, una marca comprometida en mantener al máximo la esencia de sus productos y por eso los elabora sin aditivos artificiales. Una marca transparente que muestra el listado de ingredientes siempre bien visible en el frontal de sus envases. Crónica completa de la Maratón de Tokio 2024 https://youtu.be/PKRV49KospE - Aquí tienes el vídeo de la carrera desde dentro https://youtu.be/E3RIyTDdC7s - Aquí te desgloso todos los gastos para correr esta Marathon Major https://www.palabraderunner.com/cuanto-cuesta-maraton-tokio/ - - Seguro de viaje Intermundial para cualquier país (descuento PALABRADERUNNER) https://pdrun.es/segurodeviaje - - eSIM de datos Airalo (descuento PEDRO1993) https://pdrun.es/airaloesim - - eSIM de datos ilimitada Holafly (descuento PALABRADERUNNER) https://pdrun.es/holafly - 

In this two-part series, we reprise “Navigating Clinical Trials: Expectations vs. Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. MEET TAYMEYAH AL-TOUBAH, MPHTaymeyah Al-Toubah is a clinical researcher, currently at Moffitt Cancer Center, who has been in the research field for 10 years. She began her career in 2013 while obtaining her bachelor's degrees in biomedical sciences and psychology, working in pediatric and neonatal research at Johns Hopkins All Children's Hospital. In 2016, she shifted her career focus to oncology, beginning with phase I trials and working in all solid tumors. She completed her Master of Public Health in Epidemiology in 2017 and focused her graduate thesis on neuroendocrine tumors. In 2018, she switched departments to focus exclusively on NETs.From 2018 – 2023, she was the primary NET coordinator in the GI department, managing all clinical trials while leading the GI team, managing the NET clinic coordination amongst the ancillary departments, and working on all retrospective and non-interventional NET research. She has worked on protocol development, database analysis, and manuscript writing, resulting in over 30 published manuscripts and presented her research at several national and international oncology and NET conferences, with oral abstracts at several ENETS and NANETS conferences.In April 2023, she formally transitioned to a new position as a project manager of the NET program, where she will continue to mentor new coordinators while working on protocol development and writing, manuscript writing, non-interventional clinical trials, and retrospective NET research. One of her first major projects will be to curate and develop a master database of all NET patients seen at her institution that will provide the basis for all future NET research to be published at Moffitt.She is currently on the board of one of the first NET patient advocacy groups in Florida (FLaNET Carcinoid Community), which kicked off alongside the Tampa Regional NANETS meeting in November 2022. She is an active member of NANETS on the Continuing Education and Symposium Planning committees.She plans to dedicate the remainder of her career to this disease and community. Her ultimate plan is to attend medical school, specialize in medical oncology, and continue to serve the academic NET community and patient base as a physician and clinical investigator.For more information, visit LACNETS.org.

In this two-part series, we reprise “Navigating Clinical Trials: Expectations vs. Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials.MEET TAYMEYAH AL-TOUBAH, MPHTaymeyah Al-Toubah is a clinical researcher, currently at Moffitt Cancer Center, who has been in the research field for 10 years. She began her career in 2013 while obtaining her bachelor's degrees in biomedical sciences and psychology, working in pediatric and neonatal research at Johns Hopkins All Children's Hospital. In 2016, she shifted her career focus to oncology, beginning with phase I trials and working in all solid tumors. She completed her Master of Public Health in Epidemiology in 2017 and focused her graduate thesis on neuroendocrine tumors. In 2018, she switched departments to focus exclusively on NETs.From 2018 – 2023, she was the primary NET coordinator in the GI department, managing all clinical trials while leading the GI team, managing the NET clinic coordination amongst the ancillary departments, and working on all retrospective and non-interventional NET research. She has worked on protocol development, database analysis, and manuscript writing, resulting in over 30 published manuscripts and presented her research at several national and international oncology and NET conferences, with oral abstracts at several ENETS and NANETS conferences.In April 2023, she formally transitioned to a new position as a project manager of the NET program, where she will continue to mentor new coordinators while working on protocol development and writing, manuscript writing, non-interventional clinical trials, and retrospective NET research. One of her first major projects will be to curate and develop a master database of all NET patients seen at her institution that will provide the basis for all future NET research to be published at Moffitt.She is currently on the board of one of the first NET patient advocacy groups in Florida (FLaNET Carcinoid Community), which kicked off alongside the Tampa Regional NANETS meeting in November 2022. She is an active member of NANETS on the Continuing Education and Symposium Planning committees.She plans to dedicate the remainder of her career to this disease and community. Her ultimate plan is to attend medical school, specialize in medical oncology, and continue to serve the academic NET community and patient base as a physician and clinical investigator.For more information, visit LACNETS.org.

Crónica completa de la Maratón de Tokio 2024, nuestra experiencia de todo el fin de semana, la feria del corredor, la organización, los servicios al corredor, la propia carrera. Todos los detalles. Aquí tienes el vídeo de la carrera desde dentro https://youtu.be/E3RIyTDdC7s Aquí te desgloso todos los gastos para correr esta Marathon Major https://www.palabraderunner.com/cuanto-cuesta-maraton-tokio/ - ‎ - Seguro de viaje Intermundial para cualquier país (descuento PALABRADERUNNER) https://pdrun.es/segurodeviaje - - eSIM de datos Airalo (descuento PEDRO1993) https://pdrun.es/airaloesim - - eSIM de datos ilimitada Holafly (descuento PALABRADERUNNER) https://pdrun.es/holafly - 

When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases.MEET DR. ROBERT RAMIREZ, DO, FACP Dr. Robert Ramirez is a medical oncologist specializing in the treatment of thoracic and neuroendocrine malignancies and an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, TN.  He earned his medical degree from the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine. He completed an internal medicine residency at Cooper University Hospital in Camden, New Jersey. He then completed a hematology and medical oncology fellowship at the University of Tennessee Health Sciences Center in Memphis, Tennessee and served as chief fellow. He is a Fellow of the American College of Physicians, and a member of American Society of Clinical Oncology, the International Association for the Study of Lung Cancer (IASLC), and the North American Neuroendocrine Tumor Society (NANETS).  He serves on the Board of Directors for NANETS as well as the Scientific Review and Research Committee.His clinical and research interests include neuroendocrine tumors (NETs) and lung cancer.  He has a specific interest in NETs of the lung ranging from diffuse idiopathic pulmonary neuroendocrine tumor cell hyperplasia (DIPNECH) and carcinoid tumors to small cell lung cancer and other high-grade neuroendocrine carcinomas. He is active in clinical trial design including investigator-initiated trials. He enjoys teaching residents and fellows and has multiple publications and given many lectures for the scientific community on the topics of NETs and lung cancers.TOP TEN QUESTIONSBone mets:1. When and how often do NETs spread to the bones? 2. Where in the bones are tumors? What does it mean when NETs spread to the bones? How does this compare to other cancers?3. How are bone spots found and monitored? Should they be biopsied?4. What is the treatment for bone mets? Should I have radiation? Would radiation limit my ability to get PRRT?5. Should I be on bone strengthening medication? Am I at higher risk for fractures (or breaking my bones) if I have NETs in the bones?6. Do bone mets respond to PRRT?7. Does having bone mets put me at a higher risk of MDS?Brain mets:8. When and how often do NETs spread to the brain? Do all types of NETs have the potential to spread to the brain?9.    How are brain mets found and monitored? When should I suspect this?10.  How are brain mets treated? What does having brain mets mean for my life?*Bonus: What final words of hope do you have for the neuroendocrine cancer community?For more information, visit LACNETS.org.

Yep, el titulo lo dice todo jejeje

Every year, the Commonwealth collects more revenue from HECS than it gets from the Petroleum Resource Rent Tax. The PRRT is so insufficient that gas companies love it! Mark Ogge explains the Government's proposed changes, and how we can fix it to tax our gas companies fairly. This was recorded on Tuesday 6th February 2024 and things may have changed since recording. australiainstitute.org.au // @theausinstitute Guest: Mark Ogge, Principal Advisor, the Australia Institute // @MarkOgge  Host: Ebony Bennett, Deputy Director, the Australia Institute // @ebony_bennett Producer: Jennifer Macey // @jennifermacey Edited by: Emily Perkins Theme Music: Pulse and Thrum; additional music by Blue Dot SessionsSupport Follow the Money: https://nb.australiainstitute.org.au/donateSee omnystudio.com/listener for privacy information.

In this episode, we're talking in depth about one of the most exciting and widely discussed treatments for NETs: PRRT. This is a revised version of an episode that originally released in 2020. A lot has happened since then in the development of nuclear medicine treatments like PRRT, and we're excited to bring you information […] The post NETWise Episode 28: PRRT Revisited appeared first on NETRF.

Neuroendocrine tumours (commonly referred to as NETs) is the topic for this week's episode of Oncology for the Inquisitive Mind. Michael and Josh thought it could be easily covered in a single episode, but they were wrong. This is not dissimilar to the recurrent cancellation of Futurama, a television series with nine lives saved by every network in existence.Neuroendocrine tumours are a diverse, heterogeneous, rare group of cancers that can occur throughout the body. The most common location is the gastrointestinal tract, lung, and pancreas. Of course, these aren't the only locations with NETs forming in the thymus, prostate, breast and skin. To complicate things further, the classification of NETs has changed multiple times over the past two decades.This first episode of our four-part "tour de force" will summarise well-differentiated neuroendocrine tumours and the pivotal studies of lanreotide and PRRT (peptide receptor radionucleotide therapy) with lutetium dotatate.Links to studies discussed in this episode (subscription may be required):1. Lanreotide - https://www.nejm.org/doi/full/10.1056/nejmoa13161582. PRRT - https://www.nejm.org/doi/full/10.1056/nejmoa16074273. NCCN guidelines: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdfFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Emerald's returned, meanwhile Tim Smith is threatening to. Emerald and Tom learn about the Petroleum Resource Rent Tax (PRRT) - and wonder why the government is going to make less from it than student loan indexation. Speaking of, that's the second topic! How much did the HECS-HELP indexation cost Emerald? The PM got a free education, why can't you? Finally, a call to action. Full video version of this episode available on https://www.youtube.com/c/SeriousDangerAU  Subscribe on Patreon to support the show and check out all our bonus Patreon eps with guests like Geraldine Hickey, Michael Berkman, Wil Anderson, Cam Wilson, Tom Tanuki and Jon Kudelka, and deep dives into topics like psychedelic-assisted therapy, killer robots (with Emerald's sister!), a debrief of the 2022 federal results, whether the Greens are too woke, the 18-year plan for Greens government, whether lawns should be banned, Greens memes, bad takes, Joe Hildebrand's small brain, CPAC, Aussie political sketch comedy, internal Greens party shenanigans, and whether a Greens government would lead to the apocalypse. https://www.patreon.com/SeriousDangerAU  Links - Useful explainer of PRRT -  https://www.austaxpolicy.com/budget-forum-2022-why-not-repeal-the-petroleum-resource-rent-tax-and-levy-a-royalty-for-offshore-gas/  HECS-HELP increase calculator -  https://www.abc.net.au/news/2023-06-01/hecs-calculator-how-much-has-my-hecs-gone-up-by/102410180  Get involved with the week of action on housing -  https://greens.org.au/housing/volunteer  Equality Australia is looking for stories of queer people facing discrimination in religious schools & organisations - https://www.surveymonkey.com/r/6SW26VV  Produced by Michael Griffin Follow us on Twitter, Instagram, TikTok and Patreon @SeriousDangerAUSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

On the Money Café this week, Alan Kohler and James Thomson – fully recovered from COVID and awaiting hot chocolate – discuss the first draft of Alan's avatar, the four companies making up 70 per cent of profits, localised recessions, a glut of offices, and the RBA, FOI and what the poobahs should be doing. Also: war-gaming a US default, capped admin fees for super, SMSFs, cooling the housing market, YIMBY, uranium stocks and uranium ETFs, GST and inflation, PRRT, migration, granny flats and Stephen Mayne for prime minister.See omnystudio.com/listener for privacy information.

ASX 200closed up 57 to 7277 (+0.8%) in a broad market rally. Energy sector soaring today +2.5% following news the government's PRRT hike is not as bad as feared. WDS +2.9%, BPT +2.8%, and COE +6.7%. Lithium stocks were stronger today following Morgan Stanley's comments that lithium markets have hit a turning point, MIN +1.4%, PLS +4.6%, and CXO +6.7%. Gold miners found some support down 0.7%. Staples also stumbled down 0.9%, EDV off 0.3%, and WOW slipping 1.1%. Banks recover some of last week's losses, NAB leading the way up 2%, WBC +1.8%, CBA +1%, ANZ +0.1%, while MQG fell 2.2%. The Big Bank Basket rose 1.1% to $169.79. Tech steady, All Tech Index up 0.6%, WTC +0.2%, CPU +1.1%, and XRO +1.1%. REITS better up 0.4%. Resource stocks the place to be, BHP +1.5%, RIO +2.4%, and FMG +1.9%. Healthcare and Insurance mixed, RMD -0.9%, RHC+1.2%and MPL off 0.3%. In corporate news, WBC recorded 1H23 profit of $4bn, up 22%, CEO Peter Kings says the bank is ready for a downturn as its March NIM has plateaued and would fall in the coming half. LYC +12% Malaysian operating license extended until 2024. WOR +3.6% awarded engineering and design contract by Shell for Sparta. In economic news, NAB business confidence rose 1 point to 0 in April, the highest reading since January, and Australian building permits fell 0.1% MoM, reversing from 4% growth in February. March BoJ meeting minutes indicated thoughts that market distortions remained but did not worsen. Asian markets mixed, Japan down 0.2% and HK up 0.7% with China up 1.7%. Australia's 10Y yield rose 7bps to 3.39%. Bitcoin down 1.28%. Dow Jones futures down 16 points and Nasdaq futures down 2 points. Why not sign up for a free trial? Get access to expert insights and research and become a better investor.

Treasurer Jim Chalmers says millions of Australian households will receive up to $500 in energy bill relief in the Federal Budget. He's also confirmed there will be changes to the gas industry profit tax known as the petroleum resource rent tax or PRRT. Dr Chalmers spoke to Chief Political Correspondent Anna Henderson.

There's been a shock move - and it's not Gillian on the dancefloor. The Reserve Bank Board decided to lift rates at its May meeting despite many an economist forecasting a pause. So what's going on - this episode we explain the thinking from the RBA and the impact of the rate hike. Plus, the other big economic 'thing' on the horizon - the Federal Budget. What can we expect and what are economists looking for. Superannuation changes, welfare support and the petroleum resource rent tax (PRRT)* are among some of the measures under the spotlight. Manager Economics, Impact Economics Emma Grey and Barrenjoey Senior Economist Johnathan McMenamin join Gillian to explain. *This episode was recorded, just ahead of the announcement by the Government confirming its changes to the PRRT.See omnystudio.com/listener for privacy information.

The PRRT, or Petroleum Resource Rent Tax, is a tax on profits of petroleum products, including crude oil and petroleum gas. But through accounting tricks and loopholes, gas corporations are avoiding paying their fair share of tax. Research mentioned: https://australiainstitute.org.au/report/reforming-the-petroleum-resource-rent-tax/ This was recorded on Monday 19th April 2023 and things may have changed since recording. The Australia Institute // @theausinstitute Guest: Richard Denniss, Executive Director, the Australia Institute // @RDNS_TAI Host: Ebony Bennett, Deputy Director, the Australia Institute // @ebony_bennett Producer: Jennifer Macey // @jennifermacey Edited by: Emily Perkins Theme Music: Pulse and Thrum; additional music by Blue Dot SessionsSupport Follow the Money: https://nb.australiainstitute.org.au/donateSee omnystudio.com/listener for privacy information.

This episode we speak with Dr. Sam Mehr and Scott Dengenhardt from Nebraska Cancer Specialists, two major point people on the research team about PRRT now and in the future! Please make sure to follow us on your preferred streaming platform and give us a 5 star rating! For more information please go to our website: http://www.netcancerawareness.org and follow us on social media @netcanceraware

Justin Frandson is the Founder of Bliss Intake LLC, BS, PRRT and an Athleticism Performance Coach that has worked with amateur and professional athletes for over the past two decades. We Discuss-The new level of EMF threat-How EMFs affect our health-How to protect yourself from EMFTo Learn More go to www.sarabantahealth.comTo Order Stem Cell Patches, go tohttps://lifewave.com/sarabanta/enrollment/packsClick JOIN at the top rightTo Join my FREE group coaching, Join Telegram and then click on: https://t.me/+lJZ5Li-_8nMzYmMxAccelerated Health Radio & TV is broadcast live Tuesdays at 4PM ET.Accelerated Health TV Show is viewed on Talk 4 TV (www.talk4tv.com).Accelerated Health Radio Show is broadcast on W4HC Radio - Health Café Live (www.w4hc.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).Accelerated Health Podcast is also available on Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

蘋果電腦創辦人史蒂夫・賈伯斯因罹患生長在胰臟的神經內分泌腫瘤，歷經8年治療後，最終沒能戰勝癌症，於2011年病逝，神經內分泌腫瘤因此被稱為「賈伯斯病」，引起了醫界對這種癌症治療的探索。 本集邀請臺北榮民總醫院核子醫學部醫師姚珊汎，來為大家解答什麼是神經內分泌腫瘤（NET）？它為什麼如此難察覺？罹病後會出現哪些容易和其他疾病混淆的症狀？隨著醫療科技的進步，現今已發展出肽受體－放射線核素治療（簡稱PRRT）可以醫治此病，這個賈伯斯錯過的高科技療法又是什麼？ 這集你將會聽到： -什麼是神經內分泌腫瘤（NET）？有哪些危險因子或好發族群？ -為什麼神經內分泌腫瘤這麼難發現？出現哪些症狀要提高警覺，儘早就醫？ -目前臨床上有哪些診斷與治療方式？ -神經內分泌腫瘤的剋星：肽受體－放射線核素治療（PRRT）是什麼？ 主持人：康健雜誌總主筆 張曉卉 來賓：臺北榮民總醫院核子醫學部醫師 姚珊汎 ＊癌症問康健-陪伴你解答癌症旅程大小事：https://bit.ly/3sC722v ＊意見信箱：cancerch@cw.com.tw

COR2ED Medical Education: In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or not. In patients with well-differentiated Grade 1/2 neuroendocrine tumours (NETs) and slowly progressive asymptomatic disease, potential strategies for continuing SSA at progression include increasing the SSA dose frequency from every four to every two weeks, increasing the monthly SSA dose, using SSA as maintenance therapy in stable patients unable to tolerate chemotherapy, and—in patients receiving peptide receptor radionuclide therapy (PRRT)—during and/or post PRRT. They share their clinical experience and their own clinical practice, based on data from key studies including NETTER-1, CLARINET FORTE, and REMINET, as well as relevant retrospective analyses. Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, London, UK. Dr Aman Chauhan is a Medical Oncologist and Director of NET Theranostics at the University of Kentucky Markey Cancer Center, Kentucky, USA.

Dr. Satya Nanu Das joins the show today and talks about PRRT. He also lets us know about how he got into NETs and other important tips for patients! Please make sure to follow us on your preferred streaming platform and give us a 5 star rating! For more information please go to our website: http://www.netcancerawareness.org and follow us on social media @netcanceraware

Renewal Health Center offers a unified & holistic approach to healthcare by combining the expertise of like-minded practitioners working together to create a state of complete health renewal for clients. With me on this episode is Jim Krupar, PT, PRRT and AAT practitioner, Cert, MDT, and Nicole M. Black, LMT. To run a successful business, you need resources, valuable connections and community recognition. Business Inspires will provide you with the tools, resources, and examples to inspire you to create the business you are envisioning. With more than 60 years as an integral part of the Grandview, Upper Arlington and Marble Cliff communities, the Tri-Village Chamber Partnership is dedicated to a singular purpose - the success of the business community. Thank you for downloading, listening and following Business Inspires, https://www.chamberpartnership.org/ (a Tri-Village Chamber Partnership podcast). This season is presented by:  https://marblecliff.org/ (Village of Marble Cliff), https://www.burgessniple.com/ (Burgess & Niple), https://www.grandviewheights.gov/ (City of Grandview Heights), https://datadrivenchiropractic.com/ (Optimize Chiropractic), and https://upperarlingtonoh.gov/ (City of Upper Arlington.) To schedule a guest appearance, or find out more about sponsoring Business Inspires, send an email to: David Polakowski, President/CEO, Tri-Village Chamber Partnership david@chamberpartnership.org Follow the podcast on Apple Podcasts, Google Podcasts, or your favorite podcast player. HELP US SPREAD THE WORD! We'd love it if you could please share this podcast with your social media friends!   If you liked this episode, https://www.pleasereviewmypodcast.com/secpodcast (please leave us a rating and a review in iTunes. Here's how). Discover more podcasts like this at https://www.circle270media.com (Circle270Media Podcast Consultants). Copyright 2022 Tri-Village Chamber Partnership

How can patients make decisions about where, when, and what kind of PRRT to receive? How does PRRT in the USA differ from other parts of the world? Why does each institution have different post-PRRT radiation safety precautions? What is the patient experience with traveling after PRRT? Internationally recognized patient advocate and President of NorCal CarciNET Community, Josh Mailman, answers ten common questions about the past, present, and future of PRRT. Josh, whose journey has taken him from PRRT recipient to a seat on the Nuclear Regulatory Commission Advisory Committee, shares from his years of patient advocacy work in nuclear medicine and clarifies some misunderstandings about PRRT. Listen now! For more information, visit LACNETS.org.

Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression?  NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT.  Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. Listen now! Be sure to listen to Episode 8: PRRT (Part One) with Administrative Nurse Lindy Gardner of UCLA Health. For more information, visit LACNETS.org.

Inflation, interest rates and the RBA. Warren Hogan economic advisor to Judo Bank provides his prediction of when rates will go up and by how much as well as what are the key questions for a forthcoming review of the RBA. As the Solomon Islands and China deal continues to dominate the election campaign what are the differences in each party's approach to foreign aid and is it economically viable? Stephen Howes, professor of economics at the Crawford School of Public Policy at the ANU discusses. Over ninety billion dollars in revenue could be collected from offshore gas projects if changes to the petroleum resource rent tax (PRRT) are made according to a recent Greens policy. So what is the PRRT, why hasn't it worked and why hasn't the Coalition or the ALP in the past done anything about it? Diane Kraal, senior lecturer at the Monash University's Business School explains.

Inflation, interest rates and the RBA. Warren Hogan economic advisor to Judo Bank provides his prediction of when rates will go up and by how much as well as what are the key questions for a forthcoming review of the RBA. As the Solomon Islands and China deal continues to dominate the election campaign what are the differences in each party's approach to foreign aid and is it economically viable? Stephen Howes, professor of economics at the Crawford School of Public Policy at the ANU discusses. Over ninety billion dollars in revenue could be collected from offshore gas projects if changes to the petroleum resource rent tax (PRRT) are made according to a recent Greens policy. So what is the PRRT, why hasn't it worked and why hasn't the Coalition or the ALP in the past done anything about it? Diane Kraal, senior lecturer at the Monash University's Business School explains.

Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. Listen now! (PRRT Part Two with Nuclear Medicine Physician Dr. Martin Auerbach will be released next month. Stay tuned!)For more information, visit LACNETS.org.

Nucleair geneeskundige prof. dr. Lioe-Fee de Geus-Oei uit het Leids Universitair Medisch Centrum bespreekt met nucleair geneeskundige dr. Tessa Brabander uit het Erasmus MC te Rotterdam radionuclidetherapie voor neuro-endocriene tumoren: PRRT. Tijdens dit gesprek bespreken zij welke PRRT's er zijn, de resultaten van de NETTER-1-studie, kwaliteit van leven, bijwerkingen, hoe de behandeling wordt uitgevoerd en nieuwe ontwikkelingen. Referenties Strosberg J, et al. N Engl J Med 2017;376:125-35. Strosberg JR, et al. Lancet Oncol 2021;22:1752-63.

What are the current treatment options for NETs? How do I know what treatments I should be on?  In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers ten common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. Listen now!For more information, visit LACNETS.org.

Ali Zarrinpar M.D, Brian Ramnaraign M.D. Steven Hughes M.D. and Kathryn Hitchcock M.D, discuss neuroendocrine tumor (NET) management – the state of the art in 2021, including PRRT. They give an overview of the current management of neuroendocrine tumors. They describe the use of peptide receptor radionuclide therapy for treatment for NETs and they explain when, in the course of the disease, PRRT is best given

Cancer patients battling a rare form of cancer are celebrating the permanent set up of a treatment centre in Auckland. The Health Minister announced this week patients needing Peptide Recepto Radionuclide Therapy, or PRRT, will no longer need to travel to Australia. Te Aorewa Rolleston reports.

Cancer patients battling a rare form of cancer are celebrating the permanent set up of a treatment centre in Auckland. The Health Minister announced this week patients needing Peptide Recepto Radionuclide Therapy, or PRRT, will no longer need to travel to Australia. Te Aorewa Rolleston reports.

In which the intrepid Jedis known as Chronic Table (shhhh) endeavor to save the universe from bad terps and worse stories, we puff we guff we can't friggin get enough come join us one day and puff something wonderful with us! Until then enjoy the podcast and enjoy some herb my friends!

Thomas Hope, MD. Associate Professor, Abdominal Imaging and Nuclear Medicine, UCSF. Series: "Neuroendocrine Tumor Patient Conference - UCSF" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34551]

Click to Subscribe to All Ben's Fitness & Get A Free Surprise Gift from Ben. In this February 3, 2009 podcast, Ben Greenfield features two exciting interviews! "Primal Reflex Release Technique", also known as PRRT, is sweeping the country as a fast and highly effective fix for troubling injuries, muscle spasm conditions, and annoying or frustrating pains in athletes and recreational exercisers. You've probably never heard of it because it has been flying under the radar compared to more expensive techniques or therapy modalities. In the first part of this podcast, Ben interviews Spokane physical therapist and wellness expert Jim Adcock about how PRRT actually works for problems like: -trigger points -muscle spasm -joint aches & pains -psychological stress If you have an injury you're trying to beat, you'll definitely want to listen in to this interview about primal reflex release technique! And speaking of psychological stress, the second interview in this episode is with Jolene Wilkinson, a top-notch triathlon coach over at Pacific Elite Fitness. As a pro triathlete and elite ITU competitor based out of Utah, Jolene specializes in both the mental and physical components of ultimate triathlon preparation, and in this interview, you'll find out... -Jolene's step-by-step goal setting system -What the acronym S-M-A-R-T stands for and why it can help you -How Ben Greenfield uses a simple Microsoft Word technique to plan his race season -What to do about a late-in-the-day race start like Ironman 70.3 Boise -And much more! After the interview, Ben also talks about online triathlon coaching and personal training options at Pacific Elite Fitness and the enormous amount of affordable personal guidance you can receive with a customized combination of phone calls, e-mails, and online workouts! ------------------------------------------------------------- Also Included In This Podcast: -"Delta-Tea"; Ben's Secret Energy Drink Tea Recipe - 1 packet delta-E mixed with 8oz hot water. Click here to get your hands on the delta-E that Ben talks about in the podcast episode - a powerful nutrient rich combo of Green Tea, Pomegranate,  Suntheanine (the purest form of L-Theanine) and the most bio-active form of B12 (Methylcobalamin), which supports healthy brain and nerve function. Extremely low sugar and carbohydrates, with no artificial sweeteners. -Ben Greenfield's new program "The IT Band Friection Fix" for bulletproofing your knee!Click here for this just released, step-by-step system with full video and text modules for teaching you cutting-edge training, nutritional and rehabilitation techniques to eliminate pain in the side of your knee from iliotibial band friction syndrome and tendonitis. -Get paid to feature Ben Greenfield's comprehensive calorie-burning book  "100 Ways to Boost Your Metabolism" on your website. When you feature a picture and advertisement for the book on your website, you'll also get your own FREE copy! Just click here to sign-up and get started. -Triathletes can have access to full training programs written by Ben Greenfield at a fraction of the cost of monthly coaching. Just click here to go to a website where you can review your training plan options and get a free TrainingPeaks account (P.S. Use code "BGF" for a $20 savings on any Ironman training plan). -Did you miss the January 4 LIVE TV SPECIAL on fat loss by Ben Greenfield? Watch the 60+ minute lecture "The Synergy of Fat Loss" by clicking here and getting access to a secret video page for just $4.99! -Upcoming Events: Tuesday, February 17, “Metabolic Testing 101” Learn from Ben Greenfield how exercise metabolic and resting metabolic testing can vastly improve weight loss, energy and physical performance by providing you with exact details on how to fuel your body and how to exercise at the ideal heart rate intensity for your unique physical profile.6-7pm at Pilgrim's Health Education Center in Coeur D' Alene, Idaho. Sunday, February 22nd: "Pill Poppin' With Ben - LIVE ONLINE TV SHOW AND Q&A" In this FREE live video Q&A, Ben Greenfield will demonstrate to the audience the exact pills and dietary supplements that he takes on a daily basis. He'll explain how they work, what they do, and whether or not they would be recommended for your needs. Followed by a comprehensive Q&A where you can ask your personal questions about nutritional supplements. On February 22nd, Sunday, at 6pm Pacific time, you can click here to participate in this special program. Tuesday, February 24: “Can Exercise Give You a Heart Attack?” Exercise can decrease your risk of heart attack and cardiovascular disease, but it can also be risky if you don't know what you're doing. Whether your personal heart disease risk is purely genetic, or due to poor dietary and physical habits, you'll discover from Ben Greenfield how to take the guesswork out of exercising for heart health, and learn how to stay safe during physical activity. 6-7pm at Pilgrim's Health Education Center in Coeur D' Alene, Idaho. ------------------------------------------- That's all for this episode! In the future, we have upcoming episodes on maximizing swim performance, more very exciting news about the power of oil of oregano, and a very interesting interview about goat's milk... Be sure to leave our podcast a rating in iTunes! Just click here to go to our iTunes page and leave feedback.